A Disulfidptosis-Related Gene Signature Associated with Prognosis and Immune Cell Infiltration in Osteosarcoma
Abstract
:1. Introduction
2. Materials and Methods
2.1. Data Acquisition
2.2. Disulfidptosis-Associated Subtype Identification
2.3. Gene Signature and Risk Score Formulation
2.4. Survival Prognosis Evaluation
2.5. Nomogram Model Development and Validation
2.6. Functional Enrichment Analysis
2.7. Tumor Microenvironment and Chemotherapeutic Sensitivity Examination
2.8. Statistical Analyses
3. Results
3.1. Molecular Characteristics of DRGs-Cluster Subtypes in Osteosarcoma
3.2. Building a Disulfidptosis-Related Prognostic Model
3.3. Independence Validation of the Prognostic Model
3.4. Prognostic Nomogram Construction and Validation
3.5. Gene Function Enrichment Analysis
3.6. Tumor Micro-Environment Characteristics in Risk Groups
3.7. Immune Checkpoint and Drug Sensitivity Analysis
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kumar, R.; Kumar, M.; Malhotra, K.; Patel, S. Primary Osteosarcoma in the Elderly Revisited: Current Concepts in Diagnosis and Treatment. Curr. Oncol. Rep. 2018, 20, 13. [Google Scholar] [CrossRef] [PubMed]
- Lindsey, B.A.; Markel, J.E.; Kleinerman, E.S. Osteosarcoma Overview. Rheumatol. Ther. 2017, 4, 25–43. [Google Scholar] [CrossRef] [PubMed]
- He, X.; Gao, Z.; Xu, H.; Zhang, Z.; Fu, P. A meta-analysis of randomized control trials of surgical methods with osteosarcoma outcomes. J. Orthop. Surg. Res. 2017, 12, 5. [Google Scholar] [CrossRef] [PubMed]
- Huang, X.; Zhao, J.; Bai, J.; Shen, H.; Zhang, B.; Deng, L.; Sun, C.; Liu, Y.; Zhang, J.; Zheng, J. Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study. J. Bone Oncol. 2019, 16, 100230. [Google Scholar] [CrossRef] [PubMed]
- Gaspar, N.; Occean, B.V.; Pacquement, H.; Bompas, E.; Bouvier, C.; Brisse, H.J.; Castex, M.P.; Cheurfa, N.; Corradini, N.; Delaye, J.; et al. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. Eur. J. Cancer 2018, 88, 57–66. [Google Scholar] [CrossRef]
- Liu, X.; Nie, L.; Zhang, Y.; Yan, Y.; Wang, C.; Colic, M.; Olszewski, K.; Horbath, A.; Chen, X.; Lei, G.; et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat. Cell Biol. 2023, 25, 404–414. [Google Scholar] [CrossRef]
- Koppula, P.; Zhuang, L.; Gan, B. Cystine transporter SLC7A11/xCT in cancer: Ferroptosis, nutrient dependency, and cancer therapy. Protein. Cell 2021, 12, 599–620. [Google Scholar] [CrossRef]
- Liu, X.; Zhang, Y.; Zhuang, L.; Olszewski, K.; Gan, B. NADPH debt drives redox bankruptcy: SLC7A11/xCT-mediated cystine uptake as a double-edged sword in cellular redox regulation. Genes Dis. 2021, 8, 731–745. [Google Scholar] [CrossRef]
- Huang, J.; Zhang, J.; Zhang, F.; Lu, S.; Guo, S.; Shi, R.; Zhai, Y.; Gao, Y.; Tao, X.; Jin, Z.; et al. Identification of a disulfidptosis-related genes signature for prognostic implication in lung adenocarcinoma. Comput. Biol. Med. 2023, 165, 107402. [Google Scholar] [CrossRef]
- Wang, Z.; Chen, X.; Zhang, J.; Chen, X.; Peng, J.; Huang, W. Based on disulfidptosis-related glycolytic genes to construct a signature for predicting prognosis and immune infiltration analysis of hepatocellular carcinoma. Front. Immunol. 2023, 14, 1204338. [Google Scholar] [CrossRef]
- Xu, K.; Zhang, Y.; Yan, Z.; Wang, Y.; Li, Y.; Qiu, Q.; Du, Y.; Chen, Z.; Liu, X. Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which MSH3 is a key gene during disulfidptosis. Front. Immunol. 2023, 14, 1205250. [Google Scholar] [CrossRef] [PubMed]
- Hu, G.; Yao, H.; Wei, Z.; Li, L.; Yu, Z.; Li, J.; Luo, X.; Guo, Z. A bioinformatics approach to identify a disulfidptosis-related gene signature for prognostic implication in colon adenocarcinoma. Sci. Rep. 2023, 13, 12403. [Google Scholar] [CrossRef] [PubMed]
- Zaaboub, R.; Vimeux, L.; Contremoulins, V.; Cymbalista, F.; Levy, V.; Donnadieu, E.; Varin-Blank, N.; Martin, A.; Dondi, E. Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21. Blood Adv. 2022, 6, 4691–4704. [Google Scholar] [CrossRef] [PubMed]
- Wu, B.; Song, M.; Dong, Q.; Xiang, G.; Li, J.; Ma, X.; Wei, F. UBR5 promotes tumor immune evasion through enhancing IFN-gamma-induced PDL1 transcription in triple negative breast cancer. Theranostics 2022, 12, 5086–5102. [Google Scholar] [CrossRef]
- Zheng, B.; Ren, T.; Huang, Y.; Sun, K.; Wang, S.; Bao, X.; Liu, K.; Guo, W. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J. Hematol. Oncol. 2018, 11, 16. [Google Scholar] [CrossRef]
- Zhang, T.; Guo, S.; Li, F.; Lan, X.; Jia, Y.; Zhang, J.; Huang, Y.; Liang, X.J. Imaging-guided/improved diseases management for immune-strategies and beyond. Adv. Drug Deliv. Rev. 2022, 188, 114446. [Google Scholar] [CrossRef] [PubMed]
- Zulfiqar, B.; Farooq, A.; Kanwal, S.; Asghar, K. Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives. Front. Pharmacol. 2022, 13, 1035171. [Google Scholar] [CrossRef]
- Zhao, S.; Wang, L.; Ding, W.; Ye, B.; Cheng, C.; Shao, J.; Liu, J.; Zhou, H. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework. Front. Endocrinol. 2023, 14, 1180404. [Google Scholar] [CrossRef]
- Qian, L.; Wang, F.; Lu, S.M.; Miao, H.J.; He, X.; Feng, J.; Huang, H.; Shi, R.F.; Zhang, J.G. A Comprehensive Prognostic and Immune Analysis of Ferroptosis-Related Genes Identifies SLC7A11 as a Novel Prognostic Biomarker in Lung Adenocarcinoma. J. Immunol. Res. 2022, 2022, 1951620. [Google Scholar] [CrossRef]
- Leek, J.T. svaseq: Removing batch effects and other unwanted noise from sequencing data. Nucleic. Acids Res. 2014, 42, e161. [Google Scholar] [CrossRef]
- Wilkerson, M.D.; Hayes, D.N. ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking. Bioinformatics 2010, 26, 1572–1573. [Google Scholar] [CrossRef]
- Tibshirani, R. The lasso method for variable selection in the Cox model. Stat. Med. 1997, 16, 385–395. [Google Scholar] [CrossRef]
- Blanche, P.; Dartigues, J.F.; Jacqmin-Gadda, H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat. Med. 2013, 32, 5381–5397. [Google Scholar] [CrossRef] [PubMed]
- Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic. Acids Res. 2015, 43, e47. [Google Scholar] [CrossRef] [PubMed]
- Wu, H.; Zhou, Y.; Wu, H.; Xu, L.; Yan, Y.; Tong, X.; Yan, H. CENPN Acts as a Novel Biomarker that Correlates With the Malignant Phenotypes of Glioma Cells. Front. Genet. 2021, 12, 732376. [Google Scholar] [CrossRef] [PubMed]
- Yu, G.; Wang, L.G.; Han, Y.; He, Q.Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 2012, 16, 284–287. [Google Scholar] [CrossRef]
- Hanzelmann, S.; Castelo, R.; Guinney, J. GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013, 14, 7. [Google Scholar] [CrossRef]
- Yoshihara, K.; Shahmoradgoli, M.; Martinez, E.; Vegesna, R.; Kim, H.; Torres-Garcia, W.; Trevino, V.; Shen, H.; Laird, P.W.; Levine, D.A.; et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 2013, 4, 2612. [Google Scholar] [CrossRef]
- Newman, A.M.; Liu, C.L.; Green, M.R.; Gentles, A.J.; Feng, W.; Xu, Y.; Hoang, C.D.; Diehn, M.; Alizadeh, A.A. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 2015, 12, 453–457. [Google Scholar] [CrossRef] [PubMed]
- Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [Google Scholar] [CrossRef]
- Cascini, C.; Chiodoni, C. The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response. Cells 2021, 10, 1668. [Google Scholar] [CrossRef]
- O’Kane, G.M.; Cadoo, K.A.; Walsh, E.M.; Emerson, R.; Dervan, P.; O’Keane, C.; Hurson, B.; O’Toole, G.; Dudeney, S.; Kavanagh, E.; et al. Perioperative chemotherapy in the treatment of osteosarcoma: A 26-year single institution review. Clin. Sarcoma Res. 2015, 5, 17. [Google Scholar] [CrossRef] [PubMed]
- Bao, J.H.; Lu, W.C.; Duan, H.; Ye, Y.Q.; Li, J.B.; Liao, W.T.; Li, Y.C.; Sun, Y.P. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas. Front. Immunol. 2022, 13, 933973. [Google Scholar] [CrossRef] [PubMed]
- Villa, E.; Ricci, J.E. How does metabolism affect cell death in cancer? FEBS J. 2016, 283, 2653–2660. [Google Scholar] [CrossRef]
- El Mjiyad, N.; Caro-Maldonado, A.; Ramirez-Peinado, S.; Munoz-Pinedo, C. Sugar-free approaches to cancer cell killing. Oncogene 2011, 30, 253–264. [Google Scholar] [CrossRef] [PubMed]
- Liu, X.; Olszewski, K.; Zhang, Y.; Lim, E.W.; Shi, J.; Zhang, X.; Zhang, J.; Lee, H.; Koppula, P.; Lei, G.; et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer. Nat. Cell Biol. 2020, 22, 476–486. [Google Scholar] [CrossRef] [PubMed]
- Chen, M.; Jiang, Y.; Sun, Y. KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma. Biochem. Biophys. Res. Commun. 2021, 550, 77–83. [Google Scholar] [CrossRef] [PubMed]
- Shi, Y.; Gong, M.; Deng, Z.; Liu, H.; Chang, Y.; Yang, Z.; Cai, L. Tirapazamine suppress osteosarcoma cells in part through SLC7A11 mediated ferroptosis. Biochem. Biophys. Res. Commun. 2021, 567, 118–124. [Google Scholar] [CrossRef]
- Guo, W.; Wang, X.; Lu, B.; Yu, J.; Xu, M.; Huang, R.; Cheng, M.; Yang, M.; Zhao, W.; Zou, C. Super-enhancer-driven MLX mediates redox balance maintenance via SLC7A11 in osteosarcoma. Cell Death Dis. 2023, 14, 439. [Google Scholar] [CrossRef]
- Okano, S.; Takase, M.; Iseki, K.; Toriumi, N.; Kaneda, M.; Kunishima, S. Genotype-phenotype Correlation of the p.R1165C Mutation in the MYH9 Disorder: Report of a Japanese Pedigree. J. Pediatr. Hematol. Oncol. 2015, 37, e352–e355. [Google Scholar] [CrossRef]
- Girolami, A.; Sambado, L.; Bonamigo, E.; Vettore, S.; Lombardi, A.M. Occurrence of thrombosis in congenital thrombocytopenic disorders: A critical annotation of the literature. Blood Coagul. Fibrinolysis 2013, 24, 18–22. [Google Scholar] [CrossRef]
- Yamanouchi, J.; Hato, T.; Kunishima, S.; Niiya, T.; Nakamura, H.; Yasukawa, M. A novel MYH9 mutation in a patient with MYH9 disorders and platelet size-specific effect of romiplostim on macrothrombocytopenia. Ann. Hematol. 2015, 94, 1599–1600. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Barbaro, P.; Guo, Y.; Alodaib, A.; Li, J.; Gold, W.; Ades, L.; Keating, B.J.; Xu, X.; Teo, J.; et al. Utility of next-generation sequencing technologies for the efficient genetic resolution of haematological disorders. Clin. Genet. 2016, 89, 163–172. [Google Scholar] [CrossRef]
- Arora, S.; Saha, S.; Roy, S.; Das, M.; Jana, S.S.; Ta, M. Role of Nonmuscle Myosin II in Migration of Wharton’s Jelly-Derived Mesenchymal Stem Cells. Stem. Cells Dev. 2015, 24, 2065–2077. [Google Scholar] [CrossRef] [PubMed]
- Katono, K.; Sato, Y.; Jiang, S.X.; Kobayashi, M.; Nagashio, R.; Ryuge, S.; Fukuda, E.; Goshima, N.; Satoh, Y.; Saegusa, M.; et al. Prognostic significance of MYH9 expression in resected non-small cell lung cancer. PLoS ONE 2015, 10, e0121460. [Google Scholar] [CrossRef] [PubMed]
- Zhou, W.; Fan, M.Y.; Wei, Y.X.; Huang, S.; Chen, J.Y.; Liu, P. The expression of MYH9 in osteosarcoma and its effect on the migration and invasion abilities of tumor cell. Asian Pac. J. Trop. Med. 2016, 9, 597–600. [Google Scholar] [CrossRef] [PubMed]
- Tang, X.Y.; Xiong, Y.L.; Zhao, Y.B.; Yang, J.; Shi, A.P.; Zheng, K.F.; Liu, Y.J.; Shu, C.; Jiang, T.; Ma, N.; et al. Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1-FGL1-MYH9 axis. Front. Immunol. 2022, 13, 1014053. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Tang, A.; Cui, Y.; Gong, H.; Li, H. LRPPRC facilitates tumor progression and immune evasion through upregulation of m6A modification of PD-L1 mRNA in hepatocellular carcinoma. Front. Immunol. 2023, 14, 1144774. [Google Scholar] [CrossRef] [PubMed]
- Li, W.; Dai, Y.; Shi, B.; Yue, F.; Zou, J.; Xu, G.; Jiang, X.; Wang, F.; Zhou, X.; Liu, L. LRPPRC sustains Yap-P27-mediated cell ploidy and P62-HDAC6-mediated autophagy maturation and suppresses genome instability and hepatocellular carcinomas. Oncogene 2020, 39, 3879–3892. [Google Scholar] [CrossRef]
- Liu, J.Y.; Chen, Y.J.; Feng, H.H.; Chen, Z.L.; Wang, Y.L.; Yang, J.E.; Zhuang, S.M. LncRNA SNHG17 interacts with LRPPRC to stabilize c-Myc protein and promote G1/S transition and cell proliferation. Cell Death Dis. 2021, 12, 970. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Gu, J.; Xu, F.; Zhu, Q.; Chen, Y.; Ge, D.; Lu, C. Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma. Brief. Bioinform. 2021, 22, bbaa225. [Google Scholar] [CrossRef]
- Huang, D.; Huang, D. Relationship between M6A methylation regulator and prognosis in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Heliyon 2022, 8, e10931. [Google Scholar] [CrossRef] [PubMed]
- Zhao, H.; Zhou, Q.; Shi, C.; Shao, Y.; Ni, J.; Lou, J.; Wei, S. RNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape and Clinical Significance. Med. Sci. Monit. 2021, 27, e930994. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.; Zhang, S.; Yan, X.; Shan, Y.; Liu, L.; Zhou, J.; Kuang, Q.; Li, M.; Long, H.; Lai, W. m6A regulator-mediated RNA methylation modification patterns are involved in immune microenvironment regulation of periodontitis. J. Cell. Mol. Med. 2021, 25, 3634–3645. [Google Scholar] [CrossRef] [PubMed]
- Manandhar, S.; Lee, Y.M. Emerging role of RUNX3 in the regulation of tumor microenvironment. BMB Rep. 2018, 51, 174–181. [Google Scholar] [CrossRef]
- Zhang, C.; Zheng, J.H.; Lin, Z.H.; Lv, H.Y.; Ye, Z.M.; Chen, Y.P.; Zhang, X.Y. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma. Aging 2020, 12, 3486–3501. [Google Scholar] [CrossRef]
- Niu, J.; Yan, T.; Guo, W.; Wang, W.; Zhao, Z.; Ren, T.; Huang, Y.; Zhang, H.; Yu, Y.; Liang, X. Identification of Potential Therapeutic Targets and Immune Cell Infiltration Characteristics in Osteosarcoma Using Bioinformatics Strategy. Front. Oncol. 2020, 10, 1628. [Google Scholar] [CrossRef]
- Noy, R.; Pollard, J.W. Tumor-associated macrophages: From mechanisms to therapy. Immunity 2014, 41, 49–61. [Google Scholar] [CrossRef]
- Huang, Q.; Liang, X.; Ren, T.; Huang, Y.; Zhang, H.; Yu, Y.; Chen, C.; Wang, W.; Niu, J.; Lou, J.; et al. The role of tumor-associated macrophages in osteosarcoma progression—Therapeutic implications. Cell. Oncol. 2021, 44, 525–539. [Google Scholar] [CrossRef]
- Xiao, Q.; Zhang, X.; Wu, Y.; Yang, Y. Inhibition of macrophage polarization prohibits growth of human osteosarcoma. Tumour. Biol. 2014, 35, 7611–7616. [Google Scholar] [CrossRef]
- Shao, X.J.; Xiang, S.F.; Chen, Y.Q.; Zhang, N.; Cao, J.; Zhu, H.; Yang, B.; Zhou, Q.; Ying, M.D.; He, Q.J. Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells. Acta Pharmacol. Sin. 2019, 40, 1343–1350. [Google Scholar] [CrossRef]
- Buddingh, E.P.; Kuijjer, M.L.; Duim, R.A.; Burger, H.; Agelopoulos, K.; Myklebost, O.; Serra, M.; Mertens, F.; Hogendoorn, P.C.; Lankester, A.C.; et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: A rationale for treatment with macrophage activating agents. Clin. Cancer Res. 2011, 17, 2110–2119. [Google Scholar] [CrossRef]
- Punzo, F.; Bellini, G.; Tortora, C.; Pinto, D.D.; Argenziano, M.; Pota, E.; Paola, A.D.; Martino, M.D.; Rossi, F. Mifamurtide and TAM-like macrophages: Effect on proliferation, migration and differentiation of osteosarcoma cells. Oncotarget 2020, 11, 687–698. [Google Scholar] [CrossRef]
- Cao, H.; Quan, S.; Zhang, L.; Chen, Y.; Jiao, G. BMPR2 expression level is correlated with low immune infiltration and predicts metastasis and poor survival in osteosarcoma. Oncol. Lett. 2021, 21, 391. [Google Scholar] [CrossRef]
- Zhang, G.Z.; Wu, Z.L.; Li, C.Y.; Ren, E.H.; Yuan, W.H.; Deng, Y.J.; Xie, Q.Q. Development of a Machine Learning-Based Autophagy-Related lncRNA Signature to Improve Prognosis Prediction in Osteosarcoma Patients. Front. Mol. Biosci. 2021, 8, 615084. [Google Scholar] [CrossRef] [PubMed]
- Tullius, B.P.; Setty, B.A.; Lee, D.A. Natural Killer Cell Immunotherapy for Osteosarcoma. Adv. Exp. Med. Biol. 2020, 1257, 141–154. [Google Scholar] [CrossRef] [PubMed]
- Engblom, C.; Pfirschke, C.; Pittet, M.J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 2016, 16, 447–462. [Google Scholar] [CrossRef]
- De Leo, A.; Ugolini, A.; Veglia, F. Myeloid Cells in Glioblastoma Microenvironment. Cells 2020, 10, 18. [Google Scholar] [CrossRef] [PubMed]
- Pham, T.; Roth, S.; Kong, J.; Guerra, G.; Narasimhan, V.; Pereira, L.; Desai, J.; Heriot, A.; Ramsay, R. An Update on Immunotherapy for Solid Tumors: A Review. Ann. Surg. Oncol. 2018, 25, 3404–3412. [Google Scholar] [CrossRef] [PubMed]
- Anand, N.; Peh, K.H.; Kolesar, J.M. Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma. Int. J. Mol. Sci. 2023, 24, 2858. [Google Scholar] [CrossRef]
- Speiser, D.E.; Chijioke, O.; Schaeuble, K.; Munz, C. CD4+ T cells in cancer. Nat. Cancer 2023, 4, 317–329. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chen, P.; Shen, J. A Disulfidptosis-Related Gene Signature Associated with Prognosis and Immune Cell Infiltration in Osteosarcoma. Bioengineering 2023, 10, 1121. https://doi.org/10.3390/bioengineering10101121
Chen P, Shen J. A Disulfidptosis-Related Gene Signature Associated with Prognosis and Immune Cell Infiltration in Osteosarcoma. Bioengineering. 2023; 10(10):1121. https://doi.org/10.3390/bioengineering10101121
Chicago/Turabian StyleChen, Pengyu, and Jingnan Shen. 2023. "A Disulfidptosis-Related Gene Signature Associated with Prognosis and Immune Cell Infiltration in Osteosarcoma" Bioengineering 10, no. 10: 1121. https://doi.org/10.3390/bioengineering10101121